Everything below concerns IGF-1. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
=== Chronic === Complications of cadmium poisoning include cough, anemia, and kidney failure (possibly leading to death). Cadmium exposure increases the chances of developing cancer. Similar to zinc, long-term exposure to cadmium fumes can cause lifelong anosmia.
== Types == Incubators differ from the U.S. Small Business Administration's Small Business Development Centers (and similar business support programs) in that they serve only selected clients. Congress created the Small Business Administration in the Small Business Act of July 30, 1953. Its purpose is to "aid, counsel, assist and protect, insofar as is possible, the interests of small business concerns." In addition, the charter ensures that small businesses receive a "fair proportion" of any government contracts and sales of surplus property. SBDCs work with any small businesses at any stage of development, and not only with startup companies. Many business incubation programs partner with their local SBDC to create a "one-stop shop" for entrepreneurial support. There are a number of business incubators that have focused on particular industries or on a particular business model, earning them their own name.
Implementing feed-stocks of high specific activity 99Mo solutions thus allowed for higher quality production and better separations of 99mTc from 99Mo on small alumina column using chromatography. Employing low-specific activity 99Mo under similar conditions is particularly problematic in that either higher Mo loading capacities or larger columns are required for accommodating equivalent amounts of 99Mo. Chemically speaking, this phenomenon occurs due to other Mo isotopes present aside from 99Mo that compete for surface site interactions on the column substrate. In turn, low-specific activity 99Mo usually requires much larger column sizes and longer separation times, and usually yields 99mTc accompanied by unsatisfactory amounts of the parent radioisotope when using γ-alumina as the column substrate. Ultimately, the inferior end-product 99mTc generated under these conditions makes it essentially incompatible with the current supply chain. In the last decade, cooperative agreements between the US government and private capital entities have resurrected neutron capture production for commercially distributed 99Mo/99mTc in the United States of America. The return to neutron-capture-based 99Mo has also been accompanied by the implementation of novel separation methods that allow for low-specific activity 99Mo to be utilized.
== External links == Clinical trial number NCT02559895 for "A Multicenter Assessment of ALD403 in Frequent Episodic Migraine (PROMISE 1)" at ClinicalTrials.gov Clinical trial number NCT02974153 for "Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine (PROMISE 2)" at ClinicalTrials.gov
Non-focal symptoms such as amnesia, confusion, incoordination of limbs, unusual cortical visual symptoms (such as isolated bilateral blindness or bilateral positive visual phenomena), headaches and transient loss of consciousness are usually not associated with TIA, however patient assessment is still needed. Public awareness on the need to seek a medical assessment for these non-focal symptoms is also low, and can result in a delay by patients to seek treatment Symptoms of TIAs can last on the order of minutes to one–two hours, but occasionally may last for a longer period of time. TIA is defined as ischemic events in the brain that last less than 24 hours. Given the variation in duration of symptoms, this definition holds less significance. A pooled study of 808 patients with TIAs from 10 hospitals showed that 60% lasted less than one hour, 71% lasted less than two hours, and 14% lasted greater than six hours. Importantly, patients with symptoms that last more than one hour are more likely to have permanent neurologic damage, making prompt diagnosis and treatment important to maximize recovery.
Sources: en.wikipedia.org
ClC≡CCl → 2C + Cl2 Dichloroacetylene has been reported to trimerize to hexachlorobenzene upon heating, as well as perhaps on exposure to light. While it does not undergo heat-induced polymerization, molybdenum pentachloride catalyzes its room-temperature polymerization to cis-polydichloroacetylene. Like other haloalkynes, dichloroacetylene is a strong halogen bond donor. It forms an air-stable azeotrope with ether, boiling at 32 °C, that contains 55.4 wt% DCA, corresponding to a 1:1 molar ratio. Stabilizers such as trichloroethylene can support dichloroacetylene concentrations of up to 200 parts per million in air without significant decomposition.
Although all anabolic steroids have androgenic effects, some of them paradoxically results in feminization, such as breast tissue in males, a condition called gynecomastia. These side effects are caused by the natural conversion of testosterone into estrogen and estradiol by the action of aromatase enzyme, encoded by the CYP19A1 gene. Prolonged use of androgenic-anabolic steroids by men results in temporary shut down of their natural testosterone production due to an inhibition of the hypothalamic–pituitary–gonadal axis. This manifests in testicular atrophy, inhibition of the production of sperm, sexual function and infertility. A short (1–2 months) use of androgenic-anabolic steroids by men followed by a course of testosterone-boosting therapy (e.g. clomifene and human chorionic gonadotropin) usually results in return to normal testosterone production.)
Myiasis ( my-EYE-ə-səss), also known as flystrike or fly strike, is the parasitic infestation of the body of a live animal by fly larvae (maggots) that grow inside the host while feeding on its tissue. Although flies are most commonly attracted to open wounds and urine- or feces-soaked fur, some species (including the most common myiatic flies—the botfly, blowfly, and screwfly) can create an infestation even on unbroken skin. Non-myiatic flies (such as the common housefly) can be responsible for accidental myiasis. Because some animals (particularly non-native domestic animals) cannot react as effectively as humans to the causes and effects of myiasis, such infestations present a severe and continuing problem for livestock industries worldwide, causing severe economic losses where they are not mitigated by human action. Although typically a far greater issue for animals, myiasis is also a relatively frequent disease for humans in rural tropical regions where myiatic flies thrive, and often may require medical attention to surgically remove the parasites. Myiasis varies widely in the forms it takes and its effects on those affected. Such variations depend largely on the fly species and where the larvae are located. Some flies lay eggs in open wounds, other larvae may invade unbroken skin or enter the body through the nose or ears, and still others may be swallowed if the eggs are deposited on the lips or food. There can also be accidental myiasis that Eristalis tenax can cause in humans via water containing the larvae or in contaminated uncooked food.
== Synthetic inhibitors and the structure of SFTI == By modifying the amino acid sequence of sunflower trypsin inhibitor, more specifically, sunflower trypsin inhibitor-1 (SFTI-1), researchers have been able to develop synthetic serine protease inhibitors that have specificity and improved inhibitory activity towards certain serine proteases that are found in the human body, such as tissue kallikreins and human matriptase-1. For instance, researchers from the Institute of Child Health and the Department of Chemistry of the University College London, have created two SFTI-1 analogs (I10G and I10H) by substituting residue 10 of SFTI-1 (isoleucine, I) with glycine (G) and histidine (H), respectively. Out of the two analogs, SFTI-I10H was found to be the more potent KLK5 inhibitor. Another group of researchers from the previously mentioned institute and department of the University College London, conducted further research on the development of synthetic kallikrein inhibitors by modifying the amino acid sequence of SFTI-I10H. Out of the six SFTI-I10H variants that were constructed by modifying SFTI-I10H, the first and second variant (K5R_I10H and I10H_F12W) demonstrated improved KLK5 inhibition and the sixth variant (K5R_I10H_F12W) showed dual-inhibition of KLK5 and KLK7, improved KLK5 inhibition potency, and specificity for KLK5 and KLK14. The first variant (K5R_I10H) was made by replacing residue 5 of SFTI-I10H (lysine, K) with arginine (R), and in order to get the second variant (I10H_F12W) residue 12 (phenylalanine, F) was replaced with tryptophan (W).
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.